Literature DB >> 29370370

Reply to Bazaz and Denning.

Georgios Chamilos1, Michail S Lionakis2, Dimitrios P Kontoyiannis3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29370370      PMCID： PMC6005034          DOI： 10.1093/cid/ciy039

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  12 in total

1.  Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.

Authors:  R Coppola; S Zanframundo; M Verona Rinati; M Carbotti; A Graziano; G Galati; L De Florio; V Panasiti
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-03-14       Impact factor: 6.166

2.  A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.

Authors:  L D Locati; F Perrone; B Cortelazzi; C Bergamini; P Bossi; E Civelli; C Morosi; S Lo Vullo; M Imbimbo; P Quattrone; G P Dagrada; R Granata; C Resteghini; A Mirabile; S Alfieri; E Orlandi; L Mariani; G Saibene; S Pilotti; L Licitra
Journal:  Eur J Cancer       Date:  2016-11-05       Impact factor: 9.162

3.  Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4.

Authors:  Marc Dubourdeau; Rafika Athman; Viviane Balloy; Michel Huerre; Michel Chignard; Dana J Philpott; Jean-Paul Latgé; Oumaïma Ibrahim-Granet
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

4.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

Authors:  Madeleine M Hipp; Norbert Hilf; Steffen Walter; Daniela Werth; Katharina M Brauer; Markus P Radsak; Toni Weinschenk; Harpreet Singh-Jasuja; Peter Brossart
Journal:  Blood       Date:  2008-02-29       Impact factor: 22.113

5.  Type III interferon is a critical regulator of innate antifungal immunity.

Authors:  Vanessa Espinosa; Orchi Dutta; Constance McElrath; Peicheng Du; Yun-Juan Chang; Bryan Cicciarelli; Amy Pitler; Ian Whitehead; Joshua J Obar; Joan E Durbin; Sergei V Kotenko; Amariliz Rivera
Journal:  Sci Immunol       Date:  2017-10-06

6.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

Authors:  Georgios Chamilos; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

7.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

8.  CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity.

Authors:  Xin-Ming Jia; Bing Tang; Le-Le Zhu; Yan-Hui Liu; Xue-Qiang Zhao; Sara Gorjestani; Yen-Michael S Hsu; Long Yang; Jian-Hong Guan; Guo-Tong Xu; Xin Lin
Journal:  J Exp Med       Date:  2014-09-29       Impact factor: 14.307

9.  Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors.

Authors:  Jasper F W Chan; Thomas S Y Chan; Harinder Gill; Frank Y F Lam; Nigel J Trendell-Smith; Siddharth Sridhar; Herman Tse; Susanna K P Lau; Ivan F N Hung; Kwok-Yung Yuen; Patrick C Y Woo
Journal:  Emerg Infect Dis       Date:  2015-07       Impact factor: 6.883

10.  Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.

Authors:  Kuo-Hsin Chen; Meng-Tzu Weng; Yueh-Hung Chou; Yueh-Feng Lu; Chen-Hsi Hsieh
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.